Stručni rad - Pismo uredniku
Why we should not recommend or offer fluvoxamine to COVID-19 patients?
European Journal of Clinical Pharmacology, 79 (2023), 2; 321-322. https://doi.org/10.1007/s00228-022-03447-3


Citirajte ovaj rad

Trkulja, V. (2023). Why we should not recommend or offer fluvoxamine to COVID-19 patients?. European Journal of Clinical Pharmacology, 79. (2), 321-322. doi: 10.1007/s00228-022-03447-3

Trkulja, Vladimir. "Why we should not recommend or offer fluvoxamine to COVID-19 patients?." European Journal of Clinical Pharmacology, vol. 79, br. 2, 2023, str. 321-322. https://doi.org/10.1007/s00228-022-03447-3

Trkulja, Vladimir. "Why we should not recommend or offer fluvoxamine to COVID-19 patients?." European Journal of Clinical Pharmacology 79, br. 2 (2023): 321-322. https://doi.org/10.1007/s00228-022-03447-3

Trkulja, V. (2023) 'Why we should not recommend or offer fluvoxamine to COVID-19 patients?', European Journal of Clinical Pharmacology, 79(2), str. 321-322. doi: 10.1007/s00228-022-03447-3

Trkulja V. Why we should not recommend or offer fluvoxamine to COVID-19 patients?. European Journal of Clinical Pharmacology [Internet]. 02.2023. [pristupljeno 15.06.2024.];79(2):321-322. doi: 10.1007/s00228-022-03447-3

V. Trkulja, "Why we should not recommend or offer fluvoxamine to COVID-19 patients?", European Journal of Clinical Pharmacology, vol. 79, br. 2, str. 321-322, Veljača 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:779915. [Citirano: 15.06.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.